Wells Fargo & Company Finch Therapeutics Group, Inc. Transaction History

Wells Fargo & Company

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.34 - $0.56 $0 - $1	2 Added 1.27%	159 $0
Q4 2022 Feb 13, 2023	BUY	$0.36 - $1.26 $1 - $6	5 Added 3.29%	157 $0
Q3 2022 Nov 14, 2022	BUY	$1.75 - $2.88 $176 - $290	101 Added 198.04%	152 $0
Q2 2022 Aug 12, 2022	SELL	$1.91 - $5.11 $2,920 - $7,813	-1,529 Reduced 96.77%	51 $0
Q1 2022 May 16, 2022	SELL	$5.02 - $10.47 $13,217 - $27,567	-2,633 Reduced 62.5%	1,580 $8,000

Q4 2021 Feb 14, 2022	SELL	$8.95 - $16.88 $161,046 - $303,738	-17,994 Reduced 81.03%	4,213 $42,000
Q3 2021 Nov 15, 2021	BUY	$12.2 - $16.75 $270,095 - $370,828	22,139 Added 32557.35%	22,207 $288,000
Q2 2021 Aug 16, 2021	BUY	$12.03 - $17.51 $818 - $1,190	68 New	68 $1,000

Ticker FNCH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,688,400
Market Cap $63.4M
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.